SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

6042 Cornerstone Court W, Ste B
San Diego, CA 92121
Tel: 1.858.829.3082
Fax: 1.858.481.8694
Email: info@bpsbioscience.com

Data Sheet

BCMA—CHO Recombinant Cell Line (High Expression)
Catalog #79500-H

Description
Recombinant clonal stable CHO cell line constitutively expressing full length human BCMA protein, also known as TNFRSF17, (Genbank #NM_001192). Surface expression of BCMA was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of BCMA expression (High, Medium, Low) to mimic different stages of cancer target cells with various BCMA expression levels. 79500-H is a BCMA high expresser clone B7.

Background
B-cell maturation antigen (BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and also on Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy because of its restricted expression in non-malignant tissue but almost universal expression on MM cells. CART-BCMA is an autologous T cell product engineered by lentiviral transduction to express a fully human BCMA-specific CAR (chimeric antigen receptor). CAR T cells targeting BCMA have pre-clinical anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy breakthrough designation in Multiple Myeloma.

Application
1. Useful as BCMA-expressing target cells in co-culture assay with BCMA-CAR-T cell, for both BCMA-specific cell killing assay and cytokine production assay.
2. Useful for screening and validating antibodies against BCMA and anti-BCMA CAR-T for immunotherapy research and drug discovery.
3. Useful for BCMA binding assays to screening for BCMA ligands.

Host Cell
CHO K1 cell line, Chinese Hamster Ovary

Format
Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.

Storage
Store in liquid nitrogen immediately upon receipt.

6042 Cornerstone Court W, Ste B
San Diego, CA 92121
Tel: 1.858.829.3082
Fax: 1.858.481.8694
Email: info@bpsbioscience.com

Cell Culture

Thaw Medium 3 (BPS Bioscience, #60186): Ham's F-12 medium (Hyclone #SH30526.01) supplemented with 10% FBS (Life technologies #26140-079), 1% Penicillin/Streptomycin (Hyclone #SV30010.01).

Growth Medium 3D (BPS Bioscience, #79539): Thaw Medium 3 (BPS Bioscience, #60186) plus 1 mg/ml G418 (Thermo Fisher, #11811031).

Recommended Culture Condition

Frozen Cells: Prepare a 50 ml conical tube with 10 ml of pre-warmed Thaw Medium 3 (**no G418**). Quickly thaw cells in a 37°C water bath with constant and slow agitation. Clean the outside of the vial with 70% ethanol and immediately transfer the entire content to Thaw Medium 3 (**no G418**). Avoid pipetting up and down, and gently rock the conical tube.

Spin the cells down at 150 x g for 5 minutes. Discard the medium and re-suspend the cell pellet in fresh Thaw Medium 3 (**no G418**). Transfer the entire content to a T25 flask to distribute the cells. Incubate the cells in a humidified 37°C incubator with 5% CO_2. After 48-72 hours of incubation, change to fresh Thaw Medium 3 (**no G418**), without disturbing the attached cells. Continue to change the medium every 2-3 days until the cells reach desired confluency. If slow cell growth occurs during resuscitation, increase FBS to 15% for the first week of culture. Switch to Growth Medium 3D after the first passage.

Subculture: When cells reach 90% confluency, remove the medium and GENTLY wash once with PBS (without Magnesium or Calcium). These cells are loosely adherent and detach easily so do not re-suspend the PBS directly onto the cell surface. Treat cells with 2 ml of 0.25% trypsin/EDTA and incubate for 2-3 minutes at 37°C. After confirming cell detachment by light microscopy, add 10 ml pre-warmed medium and gently pipette up and down to dissociate cell clumps. Transfer cells to a 15 ml conical tube and centrifuge at 200 x g for 5 minutes. Remove the medium and re-suspend cells in 10 ml of pre-warmed Growth Medium 3D. Dispense 5 ml of the cell suspension into a new T75 flask containing 20 ml pre-warmed media. Incubate cells in a humidified 37°C incubator with 5% CO_2. Freeze cells in freezing medium (10% DMSO in FBS) when cells reach 90% confluency. Cells have been demonstrated to be stable for at least 15 passages; BPS recommends preparing frozen stocks at an early passage so cells are not used beyond passage 20.

Mycoplasma Testing

This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.

Application References

1. Ghosh A, *et al.* CAR T cell therapy for multiple myeloma *Leuk Lymphoma. 2017* Nov; **6:**1-12

6042 Cornerstone Court W, Ste B
San Diego, CA 92121
Tel: 1.858.829.3082
Fax: 1.858.481.8694
Email: info@bpsbioscience.com

2. Sanchez E, *et al.* The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. *Expert Rev Mol Diagn.* 2018 Mar; **7:**1-11.
3. Sohail A., *et al.* Emerging immune targets for the treatment of multiple myeloma. *Immunotherapy.* 2018 Feb 1; **10(4):**265-282.
4. Sidaway P., *et al.* Anti-BCMA CAR T cells show promise in MM. *Nat Rev Clin Oncol.* 2016 Sep;**13(9):**530.

Vector and Sequence
Human BCMA (NM_001192) was cloned into pIRESneo.

MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNAILWTCLGLS
LIISLAVFVLMFLLRKINSEPLKDEFKNTGSGLLGMANIDLEKSRTGDEIILPRGLEYTVEECTCEC
IKSKPKVDSDHCFPLPAMEEGATILVTTKTNDYCKSLPAALSATEIEKSISAR

Quality Assurance



Figure 1. Expression of BCMA validated by flow cytometry. Flow cytometry using PE-conjugated anti-human BCMA (CD269) antibody (Biolegend, #357504) detects BCMA surface expression of BCMA-CHO Recombinant Cell Lines with different expression levels: #79500-H, high expresser (clone B7): green; WT CHO negative control: red.

6042 Cornerstone Court W, Ste B
San Diego, CA 92121
Tel: 1.858.829.3082
Fax: 1.858.481.8694
Email: info@bpsbioscience.com

License Disclosure: Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit the use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of BPS products to your laboratory. BPS does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact sales@bpsbioscience.com for details. Publications using this cell line should reference BPS Bioscience, Inc., San Diego.

Related Products

Product	Cat. #	Size
BCMA— CHO Recombinant Cell Line (Medium Expression)	79500-M	2 vials
BCMA— CHO Recombinant Cell Line (Low Expression)	79500-L	2 vials
Human BCMA (CD269)	90105-A	5 µg
Human BCMA (CD269)	90105-B	20 µg
Human BCMA, Fc-Fusion, Avi-Tag HiP™	79465	100 µg
Human BCMA, Fc-fusion (IgG1), Avi-Tag, Biotin-Labeled HiP™	79467	50 µg
Human BAFF	90100-1	10 µg
Human BAFF	90100-2	100 µg
Human BAFF	90100-3	1 mg
Human BAFF-R(CD268)	90103-A	10 µg
Human BAFF-R(CD268)	90103-B	50 µg